



Item 5.07 - Submission of Matters to a Vote of Security Holders

PTC Therapeutics, Inc. (the "Company") held its Annual Meeting of Stockholders on June 13, 2018. The final results for the votes regarding each proposal are set forth below.

The stockholders of the Company elected two Class II directors, each to hold office until the Company's 2021 annual meeting of stockholders or until his successor has been duly elected and qualified, as follows:

Director	For	Withheld	Broker Non-Votes
Michael Schmertzler	32,931,274	732,675	6,991,227
Glenn D. Steele, Jr., M.D., Ph.D.	19,424,828	14,239,121	6,991,227

The appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018 was ratified by the Company's stockholders with 40,516,080 votes "For," 130,251 votes "Against," and 8,845 votes "Abstained."

The non-binding advisory proposal on named executive officer compensation was approved by the Company's stockholders with 33,040,595 votes "For," 604,299 votes "Against," 19,055 votes "Abstained," and 6,991,227 broker non-votes.

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

PTC Therapeutics, Inc.

Date: June 14, 2018 By: /s/ Christine Utter  
Name: Christine Utter  
Title: Principal Financial Officer